Stock News in Focus: Constellation Pharmaceuticals, (NASDAQ:CNST)

On Friday, Constellation Pharmaceuticals, (NASDAQ:CNST) stock soared 0.77% and closed at 39.38. The stock opened the session at $39.3 and touched its highest price point at $41.28. Its recent trading capacity is 603254 shares versus to its average trading volume of 1062665 shares. The company’s stock’s lowest price point for the session stood at $38.5.CNST traded as low as $ 4.01 in the past 52 weeks, and shares hit its peak level to $59.49.

Constellation Pharmaceuticals, (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, released that it has commenced an underwritten public offering of 4.75 million shares of its common stock. All of the shares are being offered by Constellation. In addition, Constellation expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

J.P. Morgan, Jefferies and Cowen are acting as joint book-running managers for the offering. RBC Capital Markets is acting as a bookrunner, and SunTrust Robinson Humphrey is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares are being offered by Constellation pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on December 9, 2019.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Leave a Reply

Your email address will not be published. Required fields are marked *